-
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research(Post)
Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
cGAS-STING Signalling: Pathway, Regulation and Key Assays(Post)Double-stranded DNA in the cytosol is always a mistake. A virus has uncoated, a mitochondrion has ruptured, a micronucleus has burst, or a chromosome has been broken and left unrepaired. cGAS treats
Exhibition at the University of Oxford's BioEscalator(Post)Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Unlocking the Next Wave of Cancer Treatment: The Rise of CAR-T Cell Therapy(Post)A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell
Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research(Post)Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
Immunopeptidomics: Mapping the Hidden Landscape of the Cancer Immunome(Post)Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li
One Integrin Chain, Two Partners, Brain or Gut(Post)A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research(Post)Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
Fast ELISA Kits(Page)Fast ELISA Kits | Results in Under 120 Minutes | Assay Genie
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
ELISA Inter-Plate Variability: Same Sample, Different Results(Post)Quick answer On the Dog Beta-endorphin (BEP) ELISA Kit, a researcher ran the same canine serum aliquots on two plates from the same lot and saw roughly double the concentration on one
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
About Us(Page)About Assay Genie | Making Scientists Smile Since 2017
Posters(Page)Free Lab Posters — Pathway Diagrams & More | Assay Genie
Two Asthma Drugs, Opposite Eosinophil Counts, Both Working(Post)Two asthma biologics have opposite effects on the blood eosinophil count, and both of them work. Mepolizumab empties the eosinophil compartment; dupilumab can transiently raise it. If that seems cont
Top 10 Therapeutics(Page) Comparison of Assay Genie Dual Luciferase Reporter Assay (MORV0010) vs Promega (E1910): Performance Evaluation of Quenching Efficiency and Auto-luminescence(Post)Both Assay Genie MORV0010 and Promega E1910 effectively quenched Firefly luciferase before Renilla detection, minimizing signal overlap. E1910 achieved 99.95% quenching efficiency, while
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Red Blood Cell Peroxidase Interference in Competitive ELISA(Post)QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the
What Are Oligodendrocytes? Functions, Markers & Disease Links(Post)Neuroscience · Glial CellsOligodendrocytes: Myelination, Lineage Markers and DiseaseOligodendrocytes are the myelinating glia of the central nervous system. A single oligodendrocyte can wrap segments
ELISA Cross-Reactivity: Tagged Standards vs Native Samples(Post)Quick answer A researcher validating two isoform assays — the Human ALT1 (HUFI00557) and ALT2 (HUFI00593) ELISA kits — spiked the ALT2 kit's standard onto the ALT1 kit's plate and saw
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Avant le premier pipetage : plan expérimental ELISA, modèles copiables(Post)Un plan expérimental ELISA fiable repose sur six éléments non négociables: des contrôles complets (blanc, négatif, positif, matrice), des étalons pour la courbe de calibration, une série de diluti
CIDE: The New Bioinformatics Engine Unmasking Secreted Proteins for Precision Immunotherapy(Post)For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secr
The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread(Post)The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread In the intricate battlefield of the human body, the immune system’s foot soldiers, neutrophils, have long been re
The Environmental Shift: How Climate Change and Biodiversity Loss are Driving the Hantavirus Surge(Post)The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt
Anifrolumab: Transforming Lupus Treatment with Targeted Immunotherapy(Post)Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
ELISA Troubleshooting: Why You Can't Skip the Full Standard Curve(Post)Quick answer A researcher measuring dopamine in mouse brain tissue got no detectable signal and, with many samples to run, asked whether the full standard curve could be skipped to sav
Apoptosis Pathway: Death Receptor, Mitochondrial and Granzyme Routes(Post)Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cyto
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Volagidemab: A Breakthrough in GLP-1 Receptor Agonists for Metabolic Disorders(Post)Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are